Telavancin (Vibativ)

Peptide

Telavancin is a semi-synthetic lipoglycopeptide antibiotic with dual mechanism of action. FDA-approved September 2009 (cSSSI) and June 2013 (HABP/VABP). ATLAS trials (n=1794): Clinical cure 88.3% vs 87.1% vancomycin (noninferior) for cSSSI. ATTAIN trials: Approved for hospital-acquired pneumonia when alternatives not suitable. Coverage: MRSA, MSSA, Streptococci, E. faecalis. SAFETY CONCERN: Higher mortality in patients with pre-existing renal impairment; use when alternatives not suitable.

Quick Answer

What it is

Telavancin is a semi-synthetic lipoglycopeptide antibiotic with dual mechanism of action. FDA-approved September 2009 (cSSSI) and June 2013 (HABP/VABP).

Key findings

Grade A: Clinical Cure Rate - cSSSI (Skin and Soft Tissue Infections)
Grade A: Hospital-Acquired Pneumonia Efficacy (Acute Respiratory Infection (ARI))
Grade A: Nephrotoxicity Risk (Skin and Soft Tissue Infections)

Safety

Avoid in moderate-severe renal impairment unless benefit outweighs risk.
SAFETY CONCERN: FDA black box warning for increased mortality in patients with CrCl <50 mL/min in HABP/VABP trials.
Risk-benefit assessment required.

⚠️ Research Notice

This peptide information is for educational and research purposes only. Peptides may not be FDA-approved for human use and may only be legally available for research purposes. Consult qualified healthcare professionals before considering any peptide compounds.

ℹ️ Quick Facts: Telavancin (Vibativ)

Quick Facts: Telavancin (Vibativ)

Best Evidence:Grade A
Conditions Studied:2
Research Outcomes:7
Grade A Findings:4
Key Effect:Skin and Soft Tissue Infections

2 conditions · 7 outcomes

Detailed Outcomes

Clinical Cure Rate - cSSSI

ATLAS-1 & ATLAS-2 Phase 3 (n=1794): Clinical cure rate 88.3% telavancin vs 87.1% vancomycin in clinically evaluable patients. Noninferior to vancomycin for complicated skin and skin structure infections including MRSA.

none

Nephrotoxicity Risk

SAFETY CONCERN: Higher mortality in patients with pre-existing renal impairment (CrCl <50 mL/min). Avoid in moderate-severe renal impairment unless benefit outweighs risk. Monitor renal function closely. Dose adjust for CrCl <50.

moderate↑Worsens

Hospital-Acquired Pneumonia Efficacy

ATTAIN-1 & ATTAIN-2 Phase 3: Clinical cure rates comparable to vancomycin for S. aureus HABP/VABP. FDA-approved June 2013 but indicated only when alternative treatments not suitable due to safety concerns.

none↓Worsens

Mortality in Renal Impairment

SAFETY CONCERN: FDA black box warning for increased mortality in patients with CrCl <50 mL/min in HABP/VABP trials. Telavancin should only be used when alternatives not suitable. Risk-benefit assessment required.

moderate↑Worsens

Antimicrobial Activity

18 systematic reviews and preclinical studies support this finding. Evidence includes systematic reviews/meta-analyses. Primarily preclinical evidence.

moderate↑Improves

Kidney Function

4 human trials support this finding. Human clinical trial data available.

small↑Improves

Safety/Tolerability

4 systematic reviews and preclinical studies support this finding. Evidence includes systematic reviews/meta-analyses. Primarily preclinical evidence.

small↑Improves